Passa al contenuto
Merck
Tutte le immagini(2)

Documenti

D9766

Sigma-Aldrich

Dipyridamole

≥98% (HPLC), powder, phosphodiesterase V inhibitor

Sinonimo/i:

NSC 515776, NSC 619103

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali
Tutte le immagini(2)

About This Item

Formula empirica (notazione di Hill):
C24H40N8O4
Numero CAS:
58-32-2
Peso molecolare:
504.63
Numero CE:
200-374-7
Numero MDL:
MFCD00010555
Codice UNSPSC:
41106305
ID PubChem:
24277705
NACRES:
NA.77

product name

Dipyridamole, ≥98% (HPLC)

Saggio

≥98% (HPLC)

Forma fisica

powder

Colore

yellow

Punto di fusione

165-166 °C (lit.)

Solubilità

DMSO: soluble
ethanol: soluble

Ideatore

Boehringer Ingelheim

Temperatura di conservazione

room temp

Stringa SMILE

OCCN(CCO)c1nc(N2CCCCC2)c3nc(nc(N4CCCCC4)c3n1)N(CCO)CCO

InChI

1S/C24H40N8O4/c33-15-11-31(12-16-34)23-26-20-19(21(27-23)29-7-3-1-4-8-29)25-24(32(13-17-35)14-18-36)28-22(20)30-9-5-2-6-10-30/h33-36H,1-18H2
IZEKFCXSFNUWAM-UHFFFAOYSA-N

Informazioni sul gene

human ... CYP1A2(1544) , PDE10A(10846) , PDE1A(5136) , PDE1B(5153) , PDE1C(5137) , PDE2A(5138) , PDE3A(5139) , PDE3B(5140) , PDE4A(5141) , PDE4B(5142) , PDE4C(5143) , PDE4D(5144) , PDE5A(8654) , PDE6A(5145) , PDE6B(5158) , PDE6C(5146) , PDE6D(5147) , PDE6G(5148) , PDE6H(5149) , PDE7A(5150) , PDE7B(27115) , PDE8A(5151) , PDE8B(8622) , PDE9A(5152) , SLC29A1(2030)
mouse ... Slc29a1(63959)

Cerchi prodotti simili? Visita Guida al confronto tra prodotti

Descrizione generale

Dipyridamole prevents cellular uptake of adenosine. It functions as an equilibrative nucleoside transporter 1 (ENT1) inhibitor.

Applicazioni

Dipyridamole has been used:
  • to perform in vitro growth inhibition assay(40)
  • to determine its ability to prevent uterine myometrial contractions(41)
  • to determine its effects on nicotinamide adenine dinucleotide (NAD+)-induced increase in intracellular adenosine triphosphate (ATP) levels(42)
  • to prevent nicotinamide riboside (NR)-induced axonal protection(43)

Azioni biochim/fisiol

Selective inhibitor of phosphodiesterase V (PDE 5); potent coronary vasodilator drug; adenosine transport inhibitor; inhibitor of platelet aggregation.

Caratteristiche e vantaggi

This compound is a featured product for Cyclic Nucleotide research. Click here to discover more featured Cyclic Nucleotide products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.
This compound is featured on the Phosphodiesterases page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound was developed by Boehringer Ingelheim. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Codice della classe di stoccaggio

11 - Combustible Solids

Classe di pericolosità dell'acqua (WGK)

WGK 2

Punto d’infiammabilità (°F)

Not applicable

Punto d’infiammabilità (°C)

Not applicable

Dispositivi di protezione individuale

dust mask type N95 (US), Eyeshields, Gloves

Certificati d'analisi (COA)

Cerca il Certificati d'analisi (COA) digitando il numero di lotto/batch corrispondente. I numeri di lotto o di batch sono stampati sull'etichetta dei prodotti dopo la parola ‘Lotto’ o ‘Batch’.

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

Extracellular Degradation into Adenosine and the Activities of Adenosine Kinase and AMPK Mediate Extracellular NAD+-produced increases in the Adenylate Pool of BV2 Microglia under Basal Conditions
Zhang J, et al.
Frontiers in Cellular Neuroscience, 12 (2018)
Terence B Beghyn et al.
Journal of medicinal chemistry, 54(9), 3222-3240 (2011-04-21)
The dominant strategy for discovery of new antimalarial drugs relies on cell-free assays on specific biochemical pathways of Plasmodium falciparum . However, it appears that screening directly on the parasite is a more rewarding approach. The "drug to genome to
Nyoli Valentine et al.
The Cochrane database of systematic reviews, 11, CD005449-CD005449 (2012-11-16)
Cardiovascular disease (CVD) is the most prevalent complication of type 2 diabetes with an estimated 65% of people with type 2 diabetes dying from a cause related to atherosclerosis. Adenosine-diphosphate (ADP) receptor antagonists like clopidogrel, ticlopidine, prasugrel and ticagrelor impair
J A Thorn et al.
General pharmacology, 27(4), 613-620 (1996-06-01)
1. In mammals, nucleoside transport is an important determinant of the pharmacokinetics, plasma and tissue concentration, disposition and in vivo biological activity of adenosine as well as nucleoside analogues used in antiviral and anticancer therapies. 2. Two broad types of
Tochukwu C Okwuosa et al.
Pharmaceutical research, 33(11), 2704-2712 (2016-08-11)
The fabrication of ready-to-use immediate release tablets via 3D printing provides a powerful tool to on-demand individualization of dosage form. This work aims to adapt a widely used pharmaceutical grade polymer, polyvinylpyrrolidone (PVP), for instant on-demand production of immediate release
Visualizza tutti i documenti correlati

Articoli

Discover Bioactive Molecules for Nucleotides

Cyclic nucleotides like cAMP modulate cell function via PKA activation and ion channels.

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.